References
- Stevens D, Bisno A, Chambers H, et al. Practice guidelines for the diagnosis and management of skin and soft tissue infections: 2014 update by the infectious diseases society of America. Clin Inf Dis. 2014;59:147–159.
- U. S. Department of Health and Human Services. Food and drug administration, center for drug evaluation and research. guidance for industry. Acute bacterial skin and skin structure infections: developing drugs for treatment. US Department of Health Publications; 2013 Oct.
- Russo A, Concia E, Cristini F, et al. Current and future trends in antibiotic therapy of acute bacterial skin and skin-structure infections. Clin Microbiol Infect. 2016;22(Suppl 2):S27–S36.
- Gu B, Kelesidis T, Tsiodras S, et al. The emerging problem of linezolid-resistant Staphylococcus. J Antimicrob Chemother. 2013;68:4–11.
- Ikonomidis A, Grapsa A, Pavlioglou C, et al. Accumulation of multiple mutations in linezolid-resistant Staphylococcus epidermidis causing bloodstream infections; in silico analysis of L3 amino acid substitutions that might confer high-level linezolid resistance. J Chemother. 2016;10:1–4.
- Leuthner KD, Buechler KA, Kogan D, et al. Clinical efficacy of dalbavancin for the treatment of acute bacterial skin and skin structure infections (ABSSSI). Ther Clin Risk Manag. 2016;12:931–940.
- Deck DH, Jordan JM, Holland TL, et al. Single-dose oritavancin treatment of acute bacterial skin and skin structure infections: SOLO trial efficacy by Eron severity and management setting. Infect Dis Ther. 2016;5:353–361.
- Prokocimer P, De Anda C, Fang E, et al. Tedizolid phosphate vs linezolid for treatment of acute bacterial skin and skin structure infections: the ESTABLISH-1 randomized trial. Jama. 2013;309:559–569.
- Moran GJ, Fang E, Corey GR, et al. Tedizolid for 6 days versus linezolid for 10 days for acute bacterial skin and skin-structure infections (ESTABLISH-2): a randomized, double blind, phase 3, non-inferiority trial. Lancet Infect Dis. 2014;14:696–705.
- Shorr AF, Lodise TP, Corey GR, et al. Analysis of the phase 3 ESTABLISH trials of tedizolid versus linezolid in acute bacterial skin and skin structure infections. Antimicrob Agents Chemother. 2015;59:864–871.
- Lodise TP, Bidell MR, Flanagan SD, et al. Characterization of the haematological profile of 21 days of tedizolid in healthy subjects. J Antimicrob Chemother. 2016;71:2553–2558.
- Ortiz-Covarrubias A, Fang E, Prokocimer PG, et al. Efficacy, safety, tolerability and population pharmacokinetics of tedizolid, a novel antibiotic, in Latino patients with acute bacterial skin and skin structure infections. Braz J Infect Dis. 2016;20:184–192.
- Bayer AS, Abdelhady W, Li L, et al. Comparative efficacies of tedizolid phosphate, linezolid and vancomycin in a murine model of subcutaneous catheter-related biofilm infection due to methicillin-susceptible and –resistant Staphylococcus aureus. Antimicrob Agents Chemother. 2016;60:5092–5096.
- Cubist Pharmaceuticals LLC TR-701 FA vs Linezolid for the treatment of nosocomial pneumonia. Clinical trials.gov NCT02019420 . 2016.
- Baek JY, Kang CI, Kim SH, et al. In vitro activity of Tedizolid phosphate against multidrug-resistant Streptococcus pneumoniae isolates from Asian countries. Diagn Microbiol Infect Dis. 2016;85:218–220.